stockrowSoligenix Inc.
SNGX Healthcare Biotechnology
Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023.
- EPS
- +85.4%
- Free cash flow
- +37.8%
Quarter to June 2026, against a year earlier
Follow SNGX
Alert me
Soligenix Inc. (SNGX) EV/Sales
As of 5 November 2026, Soligenix Inc. (SNGX) trades at a EV/Sales of −4.1×. Over the past ten years it has ranged from −7.2× (September 2023) to 34.2× (August 2022); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −1.9× | — |
| FY2023 | 1.7× | (90.96%) |
| FY2022 | 18.6× | 47.23% |
| FY2021 | 12.6× | 11.20% |
| FY2020 | 11.4× | 130.45% |
| FY2019 | 4.9× | 1,000.80% |
| FY2018 | 0.4× | (59.13%) |
| FY2017 | 1.1× | — |
| FY2016 | −0.1× | — |
| FY2015 | 2.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | −5.1× | — |
| Mar 2024 | 4.0× | 139.24% |
| Dec 2023 | 1.7× | — |
| Sep 2023 | −1.4× | — |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −6.4× |
| SNGX Soligenix Inc. | −4.1× |
| KPRX Kiora Pharmaceuticals, Inc. compare | −0.4× |
| CRIS Curis, Inc. compare | −0.3× |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | 1.0× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.1× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 26.1× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,410× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)